Boston Scientific Corp (BSX)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $63.33B
Last updated: Nov 17, 2026 at 4:39 PM ET
Boston Scientific Corp (BSX) Statistics
Boston Scientific (BSX) has a market cap of $63.33B and an enterprise value of $74.67B. Its trailing P/E of 13.5x is below its 10-year median of 27.1x. Its share count is down 2.23% from a year earlier.
Total Valuation
Enterprise value is 17.91% above the market cap, as debt exceeds cash.
| Market Cap | $63.33B |
|---|---|
| Enterprise Value | $74.67B |
| Latest price (Nov 17, 2026) | $43.05 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.0x and 2.4x. Its year-end P/E ranged from 19.3x to 37.4x from 2016 to 2025.
| P/E Ratio | 13.5x |
|---|---|
| Forward P/E | 13.5x |
| P/S Ratio | 3.0x |
| Forward P/S | 3.0x |
| P/B Ratio | 2.4x |
| P/FCF Ratio | 18.7x |
| P/OCF Ratio | 15.0x |
| PEG Ratio | 1.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 13.5x EBITDA and 22.1x free cash flow.
| EV / Earnings | 21.4x |
|---|---|
| EV / Sales | 3.5x |
| EV / EBITDA | 13.5x |
| EV / EBIT | 18.5x |
| EV / FCF | 22.1x |
Price Statistics
The stock is down 58.08% over 52 weeks and trades 1.91% below its 50-day average.
| Beta (1Y) | 0.27 |
|---|---|
| 52-Week Change | -58.08% |
| 1-Month Change | -4.45% |
| 3-Month Change | -17.24% |
| 6-Month Change | -24.23% |
| 5-Year Change | -2.67% |
| 10-Year Change | +90.82% |
| Total Return (1Y) | -58.08% |
| Total Return (3Y CAGR) | -7.47% |
| Total Return (5Y CAGR) | +0.88% |
| Return vs SPY (1Y) | -68.18% |
| Max Drawdown (1Y) | -59.14% |
| Max Drawdown (3Y) | -61.55% |
| Sharpe Ratio (1Y) | -2.04 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $43.89 |
| 200-Day Average | $53.65 |
| 52-Week Range | $39.57 to $101.91 |
| RSI (14 Days) | 45.3 |
| Average Volume (20 Days) | 20.03M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.36x current liabilities, and total debt is 0.47x shareholder equity.
| Current Ratio | 1.36x |
|---|---|
| Quick Ratio | 0.81x |
| Debt / Equity | 0.47x |
| Debt / EBITDA | 2.18x |
| Debt / FCF | 3.59x |
| Interest Coverage | 10.72x |
Returns and Efficiency
Return on invested capital is 10.24% over the last 12 months, against a 5-year average of 6.20%.
| Return on Equity (ROE) | 13.63% |
|---|---|
| Return on Assets (ROA) | 7.69% |
| Return on Invested Capital (ROIC) | 10.24% |
| Return on Capital Employed (ROCE) | 10.21% |
| ROE (5Y Average) | 7.78% |
| ROA (5Y Average) | 4.24% |
| ROIC (5Y Average) | 6.20% |
| Asset Turnover | 0.48x |
| Inventory Turnover | 1.98x |
Taxes
Income tax took 4.46% of pretax income over the last 12 months.
| Income Tax (TTM) | $163.00M |
|---|---|
| Effective Tax Rate | 4.46% |
Scores
BSX has an Altman Z-Score of 2.98, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.98 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $21.07B over the last 12 months is up 8.87% from the 12 months before.
| Revenue | $21.07B |
|---|---|
| Revenue Growth (YoY) | +8.87% |
| Gross Profit | $14.57B |
| Operating Income | $3.93B |
| Pretax Income | $3.65B |
| Net Income | $3.49B |
| EBITDA | $5.47B |
| EBIT | $4.03B |
| Reported EPS (TTM) | $3.19 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 56.38% of the $45.46B in total assets.
| Cash and Equivalents | $609.00M |
|---|---|
| Total Debt | $11.95B |
| Net Debt | $11.34B |
| Net Debt Per Share | $7.83 |
| Working Capital | $2.18B |
| Shareholder Equity | $25.63B |
| Book Value Per Share | $17.69 |
| Tangible Book Value | $34.00M |
| Tangible Book Per Share | $0.02 |
| Total Assets | $45.46B |
| Total Liabilities | $19.59B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $903.00M of capital spending, operating cash flow left $3.33B of free cash flow.
| Operating Cash Flow | $4.23B |
|---|---|
| Capital Expenditures | $903.00M |
| Free Cash Flow | $3.33B |
| FCF Per Share | $2.30 |
| Depreciation and Amortization | $1.45B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 18.66%, against a 5-year average of 14.62%.
| Gross Margin | 69.15% |
|---|---|
| Operating Margin | 18.66% |
| Pretax Margin | 17.35% |
| Net Margin | 16.58% |
| EBITDA Margin | 25.98% |
| EBIT Margin | 19.12% |
| FCF Margin | 15.81% |
| Gross Margin (5Y Average) | 68.94% |
| Operating Margin (5Y Average) | 14.62% |
| Net Margin (5Y Average) | 10.17% |
Growth
Revenue grew 16.54% a year over 3 years, and EPS 21.27% a year.
| Revenue Growth (3Y CAGR) | +16.54% |
|---|---|
| Revenue Growth (5Y CAGR) | +15.16% |
| EPS Growth (3Y CAGR) | +21.27% |
| EPS Growth (5Y CAGR) | +26.01% |
| FCF Growth (3Y CAGR) | +57.40% |
| FCF Growth (5Y CAGR) | +26.44% |
| Operating Income Growth (3Y CAGR) | +29.88% |
| Book Value Per Share Growth (2Y CAGR) | +11.39% |
Dividends and Yields
BSX does not pay a dividend. Its free cash flow yield is 5.34%.
| Earnings Yield | 7.41% |
|---|---|
| FCF Yield | 5.34% |
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
Stock Splits
The last split was a 2-for-1 forward split on Nov 6, 2003.
| Last Split Date | Nov 6, 2003 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 10 similar companies, BSX has the 10th highest P/E.
P/E RatioPeer median 20.9x
P/S RatioPeer median 3.6x
ROICPeer median 7.46%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.95%
| P/E Ratio | 13.5x vs 20.9x median |
|---|---|
| P/S Ratio | 3.0x vs 3.6x median |
| ROIC | 10.24% vs 7.46% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.87% vs +8.95% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.98% and EPS growth at 1.31% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.98% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +1.31% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BSX
What is BSX's market cap?
Boston Scientific has a market cap of $63.33B. Its enterprise value, which adds debt and subtracts cash, is $74.67B.
What is BSX's P/E ratio?
Boston Scientific has a trailing P/E ratio of 13.5x and a forward P/E of 13.5x.
How many shares of BSX are outstanding?
Boston Scientific has 1.45B shares outstanding. The count is down 2.23% from a year earlier.
Does BSX pay a dividend?
No. Boston Scientific does not pay a dividend.
How much debt does BSX have?
Boston Scientific has $11.95B of total debt and $609.00M of cash and equivalents, a net debt position of $11.34B.
BSX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts